Determinants and Barriers to Adherence in Hypertension

  • Valentina Forni OgnaEmail author
  • Michel Burnier
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)


Hypertension is a chronic disease which needs a lifelong treatment in mostly asympatomatic patients. During the life of a patient treated for essential hypertension, many obstacles may occur which impair his/her ability to stay on therapy. In this chapter, we will review the determinants and barriers to adherence in hypertension utilizing the WHO Multidimensional Adherence Model classification, showing in which phase of the adherence process they intervene. We will review how these barriers may complicate the therapeutic history of a hypertensive patient based on a clinical case.


Barriers Demography Factors Family Drugs Healthcare systems Side effects 


  1. 1.
    Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.CrossRefPubMedGoogle Scholar
  3. 3.
    Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26(1):60–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis. 2010;213(2):598–603.CrossRefPubMedGoogle Scholar
  5. 5.
    Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens. 2003;21(6):1199–205.CrossRefPubMedGoogle Scholar
  6. 6.
    Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M, et al. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens. 2005;23(8):1575–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens. 1996;18(3–4):463–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Br Med J. 2008;336(7653):1114–7.CrossRefGoogle Scholar
  9. 9.
    Ascertaining barriers for compliance: policies for safe, effective and cost-effective use of medicines in Europe. 2012: 1–542 pp.Google Scholar
  10. 10.
    Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995;130(3 Pt 1):572–9.CrossRefPubMedGoogle Scholar
  11. 11.
    World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.Google Scholar
  12. 12.
    Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med. 2002;17(7):504–11.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Cummings KM, Kirscht JP, Binder LR, Godley AJ. Determinants of drug treatment maintenance among hypertensive persons in inner city Detroit. Public Health Rep. 1982;97(2):99–106.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Ryan AA. Medication compliance and older people: a review of the literature. Int J Nurs Stud. 1999;36(2):153–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Ogedegbe G, Mancuso CA, Allegrante JP, Charlson ME. Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. J Clin Epidemiol. 2003;56(6):520–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288(22):2880–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension. 2001;38(4):809–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Meyer D, Leventhal H, Gutmann M. Common-sense models of illness: the example of hypertension. Health Psychol. 1985;4(2):115–35.CrossRefPubMedGoogle Scholar
  19. 19.
    Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med. 1992;8(3):141–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Reach G, Guedj-Meynier D, Darne B, Herpin D. [Factors associated with medication non-adherence in uncontrolled hypertensive males and females: ODACE study]. Annales de cardiologie et d’angeiologie. 2015;64(3):222–6.Google Scholar
  21. 21.
    Boutin-Foster C, Ogedegbe G, Ravenell JE, Robbins L, Charlson ME. Ascribing meaning to hypertension: a qualitative study among African Americans with uncontrolled hypertension. Ethn Dis. 2007;17(1):29–34.PubMedGoogle Scholar
  22. 22.
    DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45(6):521–8.CrossRefPubMedGoogle Scholar
  23. 23.
    DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.CrossRefPubMedGoogle Scholar
  24. 24.
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine. 2017;96(4):e5641.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Holt E, Joyce C, Dornelles A, Morisky D, Webber LS, Muntner P, et al. Sex differences in barriers to antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc. 2013;61(4):558–64.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Maresova V, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113–20.CrossRefPubMedGoogle Scholar
  28. 28.
    Coons SJ, Sheahan SL, Martin SS, Hendricks J, Robbins CA, Johnson JA. Predictors of medication noncompliance in a sample of older adults. Clin Ther. 1994;16(1):110–7.PubMedGoogle Scholar
  29. 29.
    Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol. 2001;166(2):569–74; discussion 74–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Grimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29(1 Pt 1):8–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens. 2008;26(11):2074–84.CrossRefPubMedGoogle Scholar
  32. 32.
    McLaughlin T, Harnett J, Burhani S, Scott B. Evaluation of erectile dysfunction therapy in patients previously nonadherent to long-term medications: a retrospective analysis of prescription claims. Am J Ther. 2005;12(6):605–11.CrossRefPubMedGoogle Scholar
  33. 33.
    Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med. 2007;120(1):26–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10(7 Pt 1):697–704.CrossRefPubMedGoogle Scholar
  35. 35.
    Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health. 1996;86(12):1805–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Perreault S, Lamarre D, Blais L, Dragomir A, Berbiche D, Lalonde L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39(9):1401–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Bautista LE. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens. 2008;21(2):183–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160(1):31–7.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94(10):1782–7.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wilson IB, Rogers WH, Chang H, Safran DG. Cost-related skipping of medications and other treatments among Medicare beneficiaries between 1998 and 2000. Results of a national study. J Gen Intern Med. 2005;20(8):715–20.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wilson IB, Schoen C, Neuman P, Strollo MK, Rogers WH, Chang H, et al. Physician-patient communication about prescription medication nonadherence: a 50-state study of America’s seniors. J Gen Intern Med. 2007;22(1):6–12.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Turner BJ, Hollenbeak C, Weiner MG, Ten Have T, Roberts C. Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf. 2009;18(8):672–81.CrossRefPubMedGoogle Scholar
  43. 43.
    Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–45.CrossRefPubMedGoogle Scholar
  44. 44.
    Kivimaki M, Batty GD, Hamer M, Nabi H, Korhonen M, Huupponen R, et al. Influence of retirement on nonadherence to medication for hypertension and diabetes. CMAJ. 2013;185(17):E784–90.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Charles H, Good CB, Hanusa BH, Chang CC, Whittle J. Racial differences in adherence to cardiac medications. J Natl Med Assoc. 2003;95(1):17–27.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–54.CrossRefPubMedGoogle Scholar
  47. 47.
    Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004;43(3):566–72.CrossRefPubMedGoogle Scholar
  48. 48.
    Orth JE, Stiles WB, Scherwitz L, Hennrikus D, Vallbona C. Patient exposition and provider explanation in routine interviews and hypertensive patients’ blood pressure control. Health Psychol. 1987;6(1):29–42.CrossRefPubMedGoogle Scholar
  49. 49.
    Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22(6):864–71.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Alsabbagh MH, Lemstra M, Eurich D, Lix LM, Wilson TW, Watson E, et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health. 2014;17(2):288–96.CrossRefPubMedGoogle Scholar
  51. 51.
    Wright J, Lee C, Chambers G. Real-world effectiveness of antihypertensive drugs. Can Med Assoc J. 2000;162:190–1.Google Scholar
  52. 52.
    Hicks LS, Shaykevich S, Bates DW, Ayanian JZ. Determinants of racial/ethnic differences in blood pressure management among hypertensive patients. BMC Cardiovasc Disord. 2005;5(1):16.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Am J Hypertens. 1999;12(4 Pt 1):333–40.PubMedGoogle Scholar
  54. 54.
    Wang L. Physician-related barriers to hypertension management. Med Princ Pract. 2004;13(5):282–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Lebeau JP, Cadwallader JS, Aubin-Auger I, Mercier A, Pasquet T, Rusch E, et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract. 2014;15:130.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34.CrossRefPubMedGoogle Scholar
  57. 57.
    Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345–51.CrossRefPubMedGoogle Scholar
  58. 58.
    Turner BJ, Hollenbeak CS, Weiner M, Ten Have T, Tang SS. Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008;148(8):578–86.CrossRefPubMedGoogle Scholar
  59. 59.
    Rose AJ, Berlowitz DR, Orner MB, Kressin NR. Understanding uncontrolled hypertension: is it the patient or the provider? J Clin Hypertens. 2007;9(12):937–43.CrossRefGoogle Scholar
  60. 60.
    Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957–63.CrossRefPubMedGoogle Scholar
  61. 61.
    Aziz H, Hatah E, Makmor Bakry M, Islahudin F. How payment scheme affects patients' adherence to medications? A systematic review. Patient Prefer Adherence. 2016;10:837–50.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Schoen C, Osborn R, Doty MM, Squires D, Peugh J, Applebaum S. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff. 2009;28(6):w1171–83.CrossRefGoogle Scholar
  63. 63.
    Morrison V, Fragher E, Parveen S, Plumpton C, Cylne W, De Geest S, et al. Determinants of patient adherence to antihypertensive medication: a multi-national cross-sectional survey. 2012: 78–103 pp.Google Scholar
  64. 64.
    Schafheutle EI, Hassell K, Noyce PR, Weiss MC. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Community. 2002;10(3):187–95.CrossRefPubMedGoogle Scholar
  65. 65.
    Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314(26):1657–64.CrossRefPubMedGoogle Scholar
  66. 66.
    Flack JM, Novikov SV, Ferrario CM. Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J. 1996;17(Suppl A):16–20.CrossRefPubMedGoogle Scholar
  67. 67.
    Dusing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy—the role of adverse effects and compliance. Blood Press. 1998;7(5–6):313–5.PubMedGoogle Scholar
  68. 68.
    Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41–6.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20(4):671–81.CrossRefPubMedGoogle Scholar
  70. 70.
    Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep. 2000;2(6):515–24.CrossRefPubMedGoogle Scholar
  71. 71.
    Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637–45.CrossRefPubMedGoogle Scholar
  72. 72.
    Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther. 2001;23(12):1999–2010.CrossRefPubMedGoogle Scholar
  73. 73.
    Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270(6):713–24.CrossRefPubMedGoogle Scholar
  74. 74.
    Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ. 1997;315(7101):154–9.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Vrijens B, Sotiris A, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Fornt Pharmacol. 2017;8:100.Google Scholar
  76. 76.
    Fargher E, Plumpton C, Morrison V, Hughes D. Preferences for persistence with medications: results froma a mulit-national discrete choice experiment. 2012: 104–26 pp.Google Scholar
  77. 77.
    Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213–24.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Dunbar-Jacob J, Bohachick P, Mortimer MK, Sereika SM, Foley SM. Medication adherence in persons with cardiovascular disease. J Cardiovasc Nurs. 2003;18(3):209–18.CrossRefPubMedGoogle Scholar
  79. 79.
    Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881–4.CrossRefPubMedGoogle Scholar
  80. 80.
    Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens. 1996;9(8):719–25.CrossRefPubMedGoogle Scholar
  81. 81.
    Yiannakopoulou E, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12(3):243–9.CrossRefPubMedGoogle Scholar
  82. 82.
    Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24(2):302–16.CrossRefPubMedGoogle Scholar
  83. 83.
    Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147–52.CrossRefPubMedGoogle Scholar
  84. 84.
    George J, Shalansky SJ. Predictors of refill non-adherence in patients with heart failure. Br J Clin Pharmacol. 2007;63(4):488–93.CrossRefPubMedGoogle Scholar
  85. 85.
    Burnier M, Brown RE, Ong SH, Keskinaslan A, Khan ZM. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract. 2009;63(5):790–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611–4.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279–83.CrossRefPubMedGoogle Scholar
  88. 88.
    Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.CrossRefPubMedGoogle Scholar
  89. 89.
    Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens. 2011;13(12):898–909.CrossRefGoogle Scholar
  90. 90.
    Comte L, Vrijens B, Tousset E, Gerard P, Urquhart J. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007;34(4):549–58.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Service of Nephrology and Hypertension, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV)LausanneSwitzerland

Personalised recommendations